Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Falls in Burberry, housebuilders pile pressure on FTSE

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 06:07pm CET
The London Stock Exchange is seen attached to the building London

Heavy losses from luxury group Burberry weighed on Britain's top share index on Thursday which hit a two-week low as investors showed anxiety about the retail and housebuilding sectors.

The FTSE 100 <.FTSE> index sank 0.6 percent, slightly outperforming a sharp slump in European stocks, while mid-caps <.FTMC> dropped 1.1 percent.

Burberry (>> Burberry Group) fell 9.4 percent, its biggest one-day loss since September 2012, on the high cost of its plans to move upmarket by focusing on leather goods and fashion and cutting sales to non-luxury stores.

"Today's results were overshadowed by the strategic reset [...] which implies no sales and earnings growth in 2019 and 2020," said Berenberg luxury analysts.

"Despite the short-term downside risk to Burberry's earnings, today's strategy update left us feeling confident about the CEO's vision," they added.

Burberry's shares had gained 34 percent so far this year, outstripping the FTSE 100 which has gained just over 5 percent.

In a weak day for retailers, Sainsbury's (>> J Sainsbury) shares fell 1.8 percent after lower sales confirmed investors' fears about inflationary pressures on consumers.

"A 2 percent first-half profit beat and confirmed full-year guidance does little to change our concerns around Sainsbury's vulnerability to a weakening UK consumer outlook," said Jefferies analysts.

Marks & Spencer (>> Marks & Spencer Group) also fell 2.4 percent, while small-cap department store Debenhams (>> Debenhams Plc) sank 6.9 percent.

Housebuilders also suffered, with shares in Persimmon (>> Persimmon), Taylor Wimpey (>> Taylor Wimpey) and Barratt Developments (>> Barratt Developments) falling by 2.8 percent to 3.9 percent after a survey showed house prices in Britain were no longer rising.

Weak results added to price pressures for mid-cap builder Redrow (>> Redrow plc), which was down 6.6 percent . Bovis Homes (>> Bovis Homes Group), Crest Nicholson (>> Crest Nicholson Holdings PLC) and Bellway (>> Bellway) fell 4.9 to 5.7 percent.

"Redrow's announcement will do little to cool any jitters around market sentiment on new housing," said analysts at Davy Research.

Business media company Informa (>> Informa PLC) was the top gainer, up 4.3 percent. The company reported revenue rose in the first 10 months of 2017, buoyed by its global exhibitions business.

Outside the blue chips, a trading update weighed on Hikma (>> Hikma Pharmaceuticals), which dropped 5.5 percent after cutting its generic sales forecast again. Its partner Vectura Group (>> Vectura Group PLC) fell 7.7 percent.

Both companies are in a dispute with the U.S. Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) lung drug Advair in the U.S. market.

Inmarsat (>> Inmarsat) sank 9 percent after the satellite firm narrowed its guidance for full-year earnings.

(Reporting by Kit Rees, editing by Larry King and Alexander Smith)

By Kit Rees and Helen Reid

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
11/21 ASTRAZENECA : Reports from AstraZeneca Describe Recent Advances in Liver Metasta..
11/21 ASTRAZENECA : New Findings from AstraZeneca in the Area of Alopecia Reported (Me..
11/21 ASTRAZENECA : Reports from Astrazeneca Describe Recent Advances in Medicinal Che..
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/21 ASTRAZENECA : FDA Approves Fasenra for Severe Asthma Stemming from Immune Cell G..
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimises likely staff losses
11/20 FTSE recoups early losses as cyclicals recover
11/20 Innate Pharma SA - Third quarter 2017 report
11/20 ASTRAZENECA : New England Journal of Medicine Publishes Results of Phase III FLA..
More news
News from SeekingAlpha
11/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
11/20 Roche Rocks On With More Good News
11/20 Merck & Co. - Blue Chip Pharmaceutical At 52-Week Lows
11/20 YOUR DAILY PHARMA SCOOP : Geron's Fate, Celldex Commences Mid-Stage Study, Novar..
11/17 Denali Therapeutics Files To Raise $100 Million IPO
Financials ($)
Sales 2017 21 809 M
EBIT 2017 5 887 M
Net income 2017 2 298 M
Debt 2017 12 458 M
Yield 2017 4,10%
P/E ratio 2017 33,54
P/E ratio 2018 28,13
EV / Sales 2017 4,44x
EV / Sales 2018 4,43x
Capitalization 84 364 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 68,1 $
Spread / Average Target 2,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA12.11%84 364
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 090
ROCHE HOLDING LTD.-1.55%212 522
PFIZER8.90%211 844
MERCK AND COMPANY-6.23%148 014